CCA's Steve Abbott and Dr. Abdul Jazieh welcome Dr. Alex Adjei to discuss the overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC).
Alex A. Adjei, MD; PhD is Chairman of the Taussig Cancer Institute and the M. Frank Rudy and Margaret D. Rudy Distinguished Chair in Translational Cancer Research at Cleveland Clinic. As Chairman, he is responsible for all clinical, financial, academic, operational, professional and strategic issues pertaining to cancer medicine at Cleveland Clinic. Dr. Adjei oversees a staff of over 170 physicians and 40 Advanced Practice Providers, both at the main campus and at 18 regional centers.
Comment down below any questions that you may have, topics that you would like to be further discussed, or feel free to share your own cancer-related story!
For a free consultation with CCA's world-class oncology team, please call 513-731-CARE or visit cincinnaticanceradvisors.org.
Please consider subscribing to our channel so you never miss out on any content! 👍
7 сен 2024
